Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes and Toxicity following 3 or More Definitive Courses of Thoracic Radiation Therapy for Non-Small Cell Lung Cancer.

Clinical lung cancer·2025
Same author

Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer: A Potential Strategy for Systemic Therapy Deferral.

Journal of the National Comprehensive Cancer Network : JNCCN·2024
Same author

Salvage Reirradiation with Proton Beam Therapy for Locoregionally Recurrent Non-Small Cell Lung Cancer.

Cancers·2024
Same author

Knowledge-based planning for fully automated radiation therapy treatment planning of 10 different cancer sites.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2024
Same author

Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2024
Same author

Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer.

Cancer treatment and research communications·2022

Related Experiment Video

Updated: Jul 10, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Antiangiogenic antithrombin.

Michael S O'Reilly1

  • 1Departments of Radiation Oncology and Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. moreilly@mdanderson.org

Seminars in Thrombosis and Hemostasis
|November 15, 2007
PubMed
Summary
This summary is machine-generated.

The cleaved form of antithrombin, a protein, demonstrates potent antiangiogenic and antitumor effects. This discovery highlights the link between blood clotting pathways and angiogenesis regulation for cancer treatment.

More Related Videos

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

Venous Thrombosis Assay in a Mouse Model of Cancer
04:40

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Related Experiment Videos

Last Updated: Jul 10, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

Venous Thrombosis Assay in a Mouse Model of Cancer
04:40

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Area of Science:

  • Biochemistry
  • Oncology
  • Vascular Biology

Background:

  • Angiogenesis is crucial in physiological and pathological processes, with inhibitors under investigation for cancer therapy.
  • Antithrombin, a serpin, typically inhibits thrombin and clotting cascade enzymes.
  • Tumor growth is influenced by various biological factors, including angiogenesis.

Purpose of the Study:

  • To investigate the antiangiogenic and antitumor properties of antithrombin.
  • To explore the potential of specific antithrombin conformations in cancer treatment.
  • To elucidate the relationship between coagulation pathways and angiogenesis regulation.

Main Methods:

  • Studied inhibition of tumor growth in a human small cell lung cancer model.
  • Examined the antiangiogenic activity of cleaved, locked, and latent forms of antithrombin.
  • Assessed the effects on endothelial cells and tumor vasculature in vivo.

Main Results:

  • The cleaved conformation of antithrombin exhibited significant antiangiogenic and antitumor activity.
  • Stable locked and latent forms of intact antithrombin also inhibited angiogenesis and tumor growth.
  • Intact native antithrombin did not display these antiangiogenic effects.
  • The antiangiogenic effects were selective for endothelial cells and tumor vasculature.

Conclusions:

  • Specific conformations of antithrombin possess potent antiangiogenic and antitumor properties.
  • This finding supports the connection between clotting/fibrinolytic pathways and angiogenesis.
  • Antiangiogenic antithrombin may target endothelial cells to block the angiogenic cascade, offering a novel therapeutic strategy.